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Background & Aims: Identification of inflamma-
tory bowel disease (IBD) susceptibility genes is key
to understanding pathogenic mechanisms. Re-
cently, the North American IBD Genetics Consor-
tium provided compelling evidence for an associa-
tion between ileal Crohn’s disease (CD) and the
IL23R gene using genome-wide association scan-
ning. External replication is a priority, both to
confirm this finding in other populations and to
validate this new technique. We tested for associa-
tion between IL23R and IBD in a large independent
UK panel to determine the size of the effect and
explore subphenotype correlation and interaction
with CARD15. Methods: Eight single nucleotide
polymorphism markers in IL23R tested in the
North American study were genotyped in 1902 cases
of Crohn’s disease (CD), 975 cases of ulcerative
colitis (UC), and 1345 controls using MassARRAY.
Data were analyzed using 2 statistics, and sub-
group association was sought. Results: A highly
significant association with CD was observed, with
the strongest signal at coding variant Arg381Gln
(allele frequency, 2.5% in CD vs 6.2% in controls
[P  1.1  1012]; odds ratio, 0.38; 95% confidence
interval, 0.29–0.50). A weaker effect was seen in UC
(allele frequency, 4.6%; odds ratio, 0.73; 95% confi-
dence interval, 0.55–0.96). Analysis accounting for
Arg381Gln suggested that other loci within IL23R
also influence IBD susceptibility. Within CD, there
were no subphenotype associations or evidence of
interaction with CARD15. Conclusions: This study
shows an association between IL23R and all sub-
phenotypes of CD with a smaller effect on UC. This
extends the findings of the North American study,
providing clear evidence that genome-wide associ-
ation scanning can successfully identify true com-
plex disease genes.
It is widely recognized that knowledge regarding thegenetic basis of inflammatory bowel disease (IBD) and
other complex diseases will provide key insights into
pathogenic mechanisms. It is this fact that has spurred
efforts to identify disease susceptibility genes. Of the
many complex diseases investigated using molecular ge-
netic techniques, Crohn’s disease (CD) is exceptional in
that specific genetic variants unequivocally associated
with disease susceptibility have been successfully identi-
fied.1,2 Nonetheless, characterization of the unknown
number of remaining CD genes is required to complete
the picture and remains a priority.
CD is one of the 2 common and related forms of IBD,
the other being ulcerative colitis (UC). Within the United
Kingdom, they have a combined prevalence of approxi-
mately 4/1000.3 Both are known to have a significant
genetic contribution to their etiology, but this is stronger
for CD than UC.4 The epidemiologic evidence also sug-
gests that CD and UC share some susceptibility genes. In
2001, fine mapping of a widely replicated linkage region
on chromosome 16 led to the identification of CARD15
as a major CD susceptibility gene, with mutations lead-
ing to dysregulation of innate immune pathways.1,2
Abbreviations used in this paper: CI, conﬁdence interval; IL23R,
interleukin 23 receptor; SNP, single nucleotide polymorphism.
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CARD15 genes have subsequently been shown in meta-
analysis to predominantly determine susceptibility to il-
eal CD. Variants within a number of other genes have
been associated with CD, UC, or both,5–9 although their
exact roles in IBD susceptibility require clarification and,
in some cases, replication.
To date, pinpointing of disease genes has depended on
detailed evaluation of candidates implicated by their
function or patterns of expression or by fine mapping
within large regions identified in the course of genome-
wide linkage scans. Across the range of common diseases,
productivity of such approaches has been limited. Most
complex disease genetic studies, including many in IBD,
have been beset by poor reproducibility of results and
slow progress in identifying disease genes. This has been
attributed to a range of factors, some of the most impor-
tant being the low resolution of sib-pair linkage analysis,
use of inappropriate statistical thresholds for signifi-
cance, and poor matching of controls due to population
admixture.10 One powerful new method for the identifi-
cation of complex disease genes is genome-wide associa-
tion scanning, genotyping large panels of affected indi-
viduals and appropriately matched population controls
for hundreds of thousands of polymorphic markers
across the genome and using appropriately stringent
statistical thresholds for significance.11 Within the past
year, such studies have become technically and financially
possible using sets of markers that capture most of the
common variation across the genome using knowledge
regarding human haplotype structure available from the
International HapMap Project (http://www.hapmap
.org).12 Systematic whole-genome association studies, in
comparison with the previous gold standard of linkage
analysis, should provide substantially increased power
and resolution for detection of complex disease suscep-
tibility genes.13
Recently, the results of a 308,332-marker genome scan
in a North American panel of 547 non-Jewish case pa-
tients with CD and 548 controls were reported. Case
patients were selected as having ileal CD to reduce het-
erogeneity.14 Three markers showed a highly significant
association with CD, 2 of which were in CARD15. The
third marker was a rare coding variant rs11209026c
(1142G¡A; Arg381Gln) found in the interleukin 23 re-
ceptor (IL23R) gene on chromosome 1 (P 5.05 109).
Nine other markers showed association with P  .0001
either within IL23R or in the intergenic area with the
adjacent IL12RB2 gene. Internal replication was achieved
in the index study using both a Jewish CD case-control
cohort (peak P value, 3.36  1013) and family-based
methodologies, the latter in addition suggesting associa-
tion with UC in a small non-Jewish cohort. This finding
indicates that IL23R may have a general role in the etiol-
ogy of IBD.14
The aims of the current study were to seek replica-
tion of the association between IL23R and IBD in a
large independent North European cohort represent-
ing the full range of CD and UC phenotypes, examine
in detail genotype-phenotype relationships, explore ev-
idence for epistasis with the known CD susceptibility
gene CARD15, and provide accurate estimates of dis-
ease risk for associated variants. Replication of the
association in an independent cohort would serve 2
important purposes. First, it is key to confirming the
veracity of the original finding and the applicability of
these findings in populations outside North America.
Further, strong independent replication of the key
finding of one of the first published genome-wide
association scans would provide proof of principle that
this novel methodology can be used to identify risk
variants for complex diseases.
Subjects and Methods
Subjects
A total of 2877 individuals with IBD (1902 with
CD and 975 with UC) were recruited in 5 centers across
England and Scotland. The study was approved by the
research ethics committees at each center.
Standard clinical, radiologic, and histologic diagnostic
criteria were applied.15 Phenotypic details were obtained
by retrospective case notes review. CD phenotype was
classified by age at diagnosis, location, and behavior of
disease. Only one member of multiply affected families
was included. A total of 1.75% were of Jewish origin, and
2.25% were nonwhite. Demographic and subphenotype
data are presented in Table 1.
Control allele frequencies were obtained from 1345
individuals recruited across Britain as part of the 1958
British birth cohort.16 Cases and controls were catego-
rized into 12 broad geographical regions within Great
Britain to minimize confounding due to variation in
allele frequencies across the country.17
Table 1. Demographic Details of 2877 Individuals With IBD
Used in Case-Control Panel
CD (n  1902) UC (n  975)
Median age at diagnosis (y) 26 38.9
Gender (F/M) 1153/745 480/495
Smoking at diagnosis (%)
Never 58.4 55.0
Ex 9.4 30.3
Current 32.2 14.7
Jewish ancestry (%) 1.75 1.9
Nonwhite (%) 2.25 3.25
Surgery (%) 61.8
Location/extent (%) 32.7 ileal 16.5 rectum only
31.8 colonic 35.0 distal to
35.5 ileocolonic splenic flexure
27.1 perianal 48.5 proximal to
splenic flexure
Behavior (%) 36.5 stenosing
17.15 penetrating
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Genotyping
Genotyping of cases was undertaken with
iPLEX chemistry on a matrix-assisted laser desorption/
ionization time-of-flight MassARRAY platform (Seque-
nom, San Diego, CA). Cases were genotyped for 8
IL23R markers reported in the index study, including
the nonsynonymous single nucleotide polymorphism
(SNP) rs11209026 encoding amino acid change
Arg381Gln (primer sequences in Supplementary Table
1; see supplemental material online at www.gastro
journal.org). Two of the North American markers
(rs7517847, rs2201841) were omitted due to their loca-
tion within a sequence of interspersed low-complexity
repeats.
Genotyping of controls was undertaken at the Well-
come Trust Sanger Institute using the Illumina 550K
chip (Illumina, San Diego, CA). Concordance of geno-
type calls between the different platforms was con-
firmed by genotyping 87 control DNAs for all 8 mark-
ers using the MassARRAY platform with strong
concordance of calls between technologies—98.99% for
the 8 markers overall. There was 100% concordance for
3 markers, including the coding variant Arg381Gln
(Supplementary Table 2; see supplemental material
online at www.gastrojournal.org). The data for 1594
cases of CD genotyped for CARD15 mutations in ear-
lier studies were used to undertake analysis for evi-
dence of interaction between CARD15 and IL23R.18–21
Statistical Methods
Allele frequencies were compared between cases
and controls and between phenotypic subgroups using 2
tests of 2  2 tables. Odds ratios were calculated for the
minor allele at each SNP; confidence intervals (CIs) were
calculated using Woolf’s method.22 Pairwise SNP linkage
disequilibrium coefficients were estimated using Haplo-
view.23 Conditional association analysis was imple-
mented using COCAPHASE, a module of the UN-
PHASED program.24 This method tests for equality of
odds ratios for haplotypes identical at conditioning loci.
The Mantel–Haenszel test for association conditioning
on geographical region was implemented using PLINK
(http://pngu.mgh.harvard.edu/purcell/plink/). Median
age at disease diagnosis between groups was compared
using the Wilcoxon rank sum test. Age at diagnosis was
dichotomized according to the Montreal classification.25
Unless specified otherwise, all analyses were performed
using R version 2.2 for Windows (http://www.R-
project.org).
Results
All genotypes were in Hardy–Weinberg equilib-
rium in both cases and controls (P  .05). A highly
significant association with CD was observed across the
region (Table 2). The strongest association was observed
at the nonsynonymous SNP Arg381Gln, where the fre-
quency of the A allele was 2.5% in CD compared with
6.2% in controls (P 1.11012). The odds ratio for this
protective allele was 0.38 (95% CI, 0.29–0.50). Alterna-
tively, the common wild-type homozygous GG genotype
can be considered as the risk genotype with an odds ratio
of 2.70. To minimize potential confounding from re-
gional differences in allele frequencies, a Mantel–Haens-
zel test was performed across 12 regional strata. Mantel–
Haenszel odds ratios was very similar to those obtained
from pooled data for all SNPs. For example, the Mantel–
Haenszel odds ratio was 0.36 (95% CI, 0.25–0.51) for
Arg381Gln.
Several SNPs also showed significant association with
UC (Table 2). The strongest signal was observed with
common SNPs rs1004819 (P .0071) and rs10889677 (P
 .0042). The frequency of Arg381Gln was only margin-
ally different between cases and controls (UC, 0.046;
controls, 0.062; P .029), with an odds ratio of 0.73 (95%
CI, 0.55–0.96). The nonsynonymous SNP Arg381Gln was
in tight linkage disequilibrium with one other SNP
(rs11465804, r2  0.85) but weak linkage disequilibrium
with all 6 other SNPs (r2  0.03–0.1). A separate test for
CD association was performed for each SNP condition-
ing on Arg381Gln by conditional regression modeling.
This showed a significant association at all SNPs (P 
.001) except rs11465804, with the strongest residual as-
sociation detected at rs10889677 (P  4.6  108).
Hence, the nonsynonymous SNP does not account for all
the association signal at this locus.
Data were then analyzed for evidence of significant
genotype-phenotype correlations based on age at onset of
CD, disease location, and disease behavior (Table 3). No
Table 2. Case-Control Allele Frequencies and Disease Odds Ratios (95% Confidence Intervals) for CD and UC
SNP Allele Controls CD P Odds ratio (95% CI) UC P Odds ratio (95% CI)
rs1004819 T 0.307 0.383 1.1  108 1.41 (1.23–1.56) 0.348 .00713 1.20 (1.05–1.37)
rs10489629 G 0.448 0.372 1.8  108 0.73 (0.66–0.82) 0.43 .26 0.93 (0.82–1.05)
rs11465804 G 0.058 0.025 7.2  1011 0.41 (0.31–0.53) 0.046 .081 0.77 (0.58–1.02)
rs11209026 A 0.062 0.025 1.1  1012 0.38 (0.29–0.50) 0.046 .0291 0.73 (0.55–0.96)
rs1343151 T 0.332 0.266 1.1  107 0.73 (0.65–0.82) 0.315 .26 0.92 (0.81–1.06)
rs10889677 A 0.315 0.398 3.4  1010 1.45 (1.28–1.61) 0.358 .0042 1.22 (1.07–1.39)
rs11209032 A 0.320 0.390 1.3  107 1.35 (1.22–1.52) 0.3524 .032 1.16 (1.01–1.32)
rs1495965 G 0.447 0.517 3.4  107 1.32 (1.19–1.47) 0.457 .57 1.04 (0.92–1.18)
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significant subgroup association was observed. In partic-
ular, the subgroup of subjects with CD affecting the
colon only without small bowel disease (n  539) ap-
peared to be as strongly associated as those with exclu-
sively ileal/small bowel involvement (n  668) (minor
allele frequencies, 2.3% and 2.0%, respectively). The age at
disease onset ranged from 12 to 67 years in patients with
CD who carried the A allele of Arg381Gln and from 0 to
80 years in wild-type GG cases. There was no difference in
the median age of onset between these 2 groups (AA/AG:
median, 28 years [n  85]; GG: median, 26 years [n 
1650]; P  .26). Stratification of cases by age at diagnosis
according to the Montreal classification25 revealed simi-
lar genotype frequencies in all groups (Table 3). For UC,
subgroup analysis by disease extent, smoking history, and
sex also revealed no significant subgroup association. Age
at onset of UC ranged from 14 to 79 years in cases who
carried the A allele of Arg381Gln and from 2 to 81 years
in wild-type GG cases, with no difference in the median
age of onset between the 2 groups (AA/AG: median, 34
years [n  72]; GG: median, 33 years [n  708]; P  .14)
(Table 4). A total of 1540 subjects with CD were fully
genotyped for the 3 CARD15mutations (G908R, L1007fs,
R702W) (Table 3). The frequency of Arg381Gln in 460
cases carrying at least one CARD15 mutation (2.2%) was
not significantly different from that in 1081 cases who
carried none (2.7%; P  .47). None of the 3 cases who
were homozygous for the rare A allele also carried a
CARD15 mutation.
Discussion
This study provides unequivocal confirmation
of association between variants in the IL23R gene and
IBD, suggesting a major effect on overall susceptibility
to CD and a more modest effect on UC. Importantly,
this study also shows the association at IL23R for the
first time in a non-American population. The strength
of this association at IL23R and the fact that it reaches
such a magnitude in 2 independent data sets leaves no
doubt that it is a true finding. In addition, this is one
of the first instances of highly significant, independent
replication of data derived from a genome-wide asso-
ciation scan and provides important validation of this
technique as a hypothesis-free method for the identi-
fication of complex disease genes.
Table 3. Arg381Gln Genotype and Allele Frequencies in CD Cases Stratified by Known Phenotypic Subgroups and CARD15
Status
AA AG GG Total Freq(A)
Sex
Male 1 36 690 727 0.026
Female 2 49 1068 1119 0.024
Smoking history
No 1 28 729 758 0.020
Yes 1 21 414 436 0.026
Ex 0 1 127 128 0.004
Disease location
Pure colorectal disease 1 23 515 539 0.023
Pure ileal disease 0 31 533 564 0.027
Ileocolonic disease 1 25 642 668 0.020
Any colorectal disease 2 46 1101 1149 0.022
Any ileal disease 1 54 1115 1170 0.024
Perianal disease
Yes 2 20 454 476 0.025
No 1 59 1205 1265 0.024
Disease behavior
Stenosing 1 32 604 637 0.027
Penetrating 2 15 248 265 0.036
Inflammatory only 0 30 714 744 0.020
Surgery
Yes 2 51 1035 1088 0.025
No 1 31 645 677 0.024
Age at diagnosis (y)
16 or younger 1 8 197 206 0.024
17–40 2 60 1129 1191 0.027
Older than 40 0 14 324 338 0.021
CARD15 statusa
/  3 52 1025 1080 0.027
/ 0 15 342 357 0.021
/ 0 5 98 103 0.024
aSamples are subdivided by CARD15 status into those homozygous wild-type (/ ), those heterozygous for CD-associated variants (/), and
those homozygous or compound heterozygous for CD-associated variants (/).
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As with the North American genome-wide scan, the
strongest evidence for association was seen at the non-
synonymous SNP Arg381Gln, where the frequency of the
A allele was 2.5% in CD compared with 6.2% in controls
(P  1.1  1012). These allele frequencies are similar to
those seen in the North American panel.14 There was no
evidence that IL23R variants associate with any particular
subphenotype of CD based on disease behavior or loca-
tion. Hence, there was no difference in minor allele fre-
quency even between the extremes of pure ileal/small
bowel CD and pure colonic CD (2.7% and 2.3%, respec-
tively). Likewise, analysis based on disease behavior did
not show any specific subgroup associations (Table 3).
This negative result is interesting because it contrasts
with the other confirmed CD susceptibility locus
CARD15, which seems to have definite associations with
ileal disease.26 These findings are extended by the obser-
vation of association with UC overall but not with any
known UC subphenotype group, suggesting that IL23R
variants may exert a rather generic effect on chronic
intestinal inflammation, although the effect size in UC
does appear to be smaller than in CD. It is noteworthy
that the odds ratio confidence interval at Arg381Gln for
UC (0.73 [95% CI, 0.55–0.96]) does not overlap with that
for CD (0.38 [95% CI, 0.29–0.50]), suggesting a signifi-
cantly less marked protective effect of the rare allele for
UC compared with CD.
Based on data from our large, independent panel of
CD cases, it is possible to provide an accurate estimate of
the size of the effect conferred by IL23R variants with
regard to the risk of CD. We estimated an odds ratio of
0.38 (95% CI, 0.29–0.49) for Arg381Gln. This is likely to
be a more accurate estimate than that provided in the
index report from the North American study (odds ratio,
0.26; 95% CI, 0.15–0.43) due to the well-recognized bias
of the so-called “winner’s curse,” which leads to overes-
timation of effect size in discovery panels.27 Characteriz-
ing the exact effect size is important to permit sample
size calculation for any further attempts at replication.
Where the effect size is overestimated, there is a risk that
apparently appropriately powered studies will fail to ob-
serve the effect and erroneously conclude that it is a false
positive.
In some previous reports of genetic association, effect
sizes have been quantitated as a population-attributable
risk in addition to the odds ratio. This figure is intended
to estimate the proportion of disease incidence attribut-
able to a specific variant. However, it cannot be calculated
for a protective minor allele as in the case of Arg381Gln.
Further, while it is possible to think of the effect at
Arg381Gln as an increased risk conferred by the common
G allele, calculations of population-attributable risk
based on this assumption lead to an implausibly high
figure due to the very high carriage rate of the G allele in
the control population.
One important question is whether the nonsynony-
mous variant accounts for all of the association signal at
IL23R. This was tested by conditional regression model-
ing, looking for evidence of association while controlling
for the effect at Arg381Gln. From this analysis, it is clear
that there is a strong residual signal, maximal at
rs10889677 (P  4.6  108), and hence that variation at
loci in addition to Arg381Gln, either within or adjacent
to IL23R, exert an influence on IBD susceptibility.
Whether this reflects a functional impact of the noncod-
ing variants themselves or the fact that they are in linkage
disequilibrium with other functionally significant or cod-
ing variants is yet to be established. Analysis within
Haploview (http://www.broad.mit.edu/mpg/haploview/)
of data available from the International HapMap
Project28 (http://www.hapmap.org) shows that this selec-
tion of 8 tag SNPs captures only 18 out of 83 informative
SNPs, within IL23R and the 3= intergenic region covered
by these markers, genotyped in the CEPH (Utah residents
with ancestry from northern and western Europe) panel
at r2  0.8. Any additional coding variation is likely to be
rare because interrogation of Ensembl database release 41
(October 2006) (http://www.ensembl.org/) revealed the
Table 4. Arg381Gln Genotype and Allele Frequencies in UC Cases Stratified by Known Phenotypic Subgroups
AA AG GG Total Freq(A)
Sex
Male 1 41 447 489 0.044
Female 2 43 436 481 0.049
Smoking history
No 0 28 301 329 0.043
Yes 0 7 81 88 0.040
Ex 1 20 160 181 0.061
Disease extent
Rectum only 1 12 134 147 0.048
Distal to splenic flexure 1 24 286 311 0.042
Proximal to splenic flexure 1 43 387 431 0.052
Age at diagnosis (y)
16 or younger 0 2 39 41 0.025
17–40 1 41 443 485 0.044
Older than 40 0 28 228 256 0.055
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presence of only 2 additional nonsynonymous coding
variants (rs1884444 and rs7530511) in IL23R with minor
allele frequency 1% in healthy European populations,
both of which were investigated in the North American
study with neither showing evidence of association. How-
ever, it is known that different splice isoforms of IL23R
exist and it is possible that their expression is determined
by some of the documented noncoding variation.29 To
clarify these issues, future studies will need to include
resequencing of IL23R in a CD panel and fine mapping
across the gene using markers identified as a result, as
well as studies to assess the potential functional impact
of variants identified.
The data with regard to Arg381Gln provide evidence of
a very common variant being a disease risk allele, or
conversely protection from CD being conferred by the
rare allele. The explanations are likely to be complex but
for immune-mediated conditions may include the fact
that genetic variation at a particular locus confers a
spectrum of risk, being protective against some diseases,
such as infections, while increasing the risk of others,
such as autoimmunity or inflammatory conditions.
These variations will have been subject to differing selec-
tion pressures in diverse populations as a result of dif-
ferent environmental exposures. It is also noteworthy
that for some of the markers showing evidence of asso-
ciation, it is the rarer allele that is associated with in-
creased risk of CD. This further supports the argument
for more than one variant in IL23R with different effects
on gene function.
Recent studies have identified IL-23, the cognate ligand
of IL23R, as a key player in both innate and adaptive
immune systems. Most IL-23 is secreted by activated
dendritic cells, monocytes, and macrophages following
their exposure to pathogen-derived molecules that bind
at toll-like receptors.30 IL-23 stimulates a unique CD4
helper T-cell population characterized by the production
of IL-17, tumor necrosis factor, and IL-6 and known as
Th17 cells. These cells play a central role in driving
autoimmune inflammation in a number of animal mod-
els. IL-17 stimulates monocytes and endothelial cells to
produce proinflammatory mediators, which in turn pro-
mote rapid neutrophil recruitment.30 The effect of IL-23
has recently been distinguished from that of the related
heterodimer IL-12, with which it shares a common p40
subunit.31 Importantly in this regard, 2 studies in knock-
out mice lacking the p19 subunit of IL-23 showed
marked attenuation of T cell–mediated colitis, while
knockout of the p35 subunit of IL-12 produces no such
attenuation, suggesting that IL-23 but not IL-12 is essen-
tial for the development of colitis.32,33 The identification
of different roles for IL-12 and IL-23 in control of im-
mune pathways together with the current genetic data
suggest that targeting IL-23 (and components of its
downstream effector pathway) may be a useful and spe-
cific strategy to inhibit IBD while sparing systemic host
protective immunity.34
As well as focusing attention on the IL-23 pathway in
the pathogenesis of IBD, the current study also provides
key validation of genome-wide association scanning as a
means of identifying complex disease susceptibility
genes. The North American study group applied an ap-
propriate, genome-wide significance level, and use of
such a stringent threshold has immediately led to repli-
cation in our independent panel with a level of signifi-
cance that makes the association indisputable.
To date, complex disease genetic studies have been
beset by poor study design, particularly use of noncon-
servative thresholds for significance, resulting in publica-
tion of many unreplicated false-positive results across the
spectrum of common disease, hence the importance of
the current study in providing unequivocal early replica-
tion in an independent panel of the principal findings
from one of the first reported genome-wide association
scans. There are recent reports in another complex dis-
ease (age-related macular degeneration) that also provide
grounds for optimism that this technique produces rep-
licable genetic association data.35–37 The clear message is
that genome-wide association scanning works and that
this study design, which is being so vigorously applied
across a number of common diseases, is likely to be
highly productive. The hope is that with use of appro-
priately stringent statistical thresholds and appropriately
powered data sets, the success seen here in CD will be
generally applicable without the plethora of false-positive
results that have vexed the field of complex disease ge-
netics to date.
Appendix
Supplementary Data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1053/j
.gastro.2007.02.051.
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